aripiprazole has been researched along with Diabetes Mellitus, Adult-Onset in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Abad-Santos, F; Cigudosa, JC; Ferreira, V; Grajales, D; Hitos, AB; Koller, D; Leibowitz, G; Mirasierra, M; Quesada, I; Ruíz-Rosario, M; Tirosh, B; Tudurí, E; Vallejo, M; Valverde, ÁM; Vázquez, P; Zubiaur, P | 1 |
| Chang, CK; Chen, CH; Chen, PY; Chiu, CC; Fang, SC; Huang, MC; Hwang, LL; Lu, ML; Mondelli, V | 1 |
| Ahmed, F; Eriksson, JW; Fanni, G; Ferreira, V; Hetty, S; Pereira, MJ; Sarsenbayeva, A; Valverde, ÁM; Vranic, M | 1 |
| Lysaker, PH; McEvoy, JP; O'Sullivan, AK; Sun, X; Weiden, PJ | 1 |
| Fujita, J; Iida, J; Negoro, H; Okada, T; Okumura, Y; Saito, T; Tsujii, N; Usami, M | 1 |
| Edelsohn, GA | 1 |
| Arnoldy, R; Curtis, J; Samaras, K | 1 |
| Citrome, L; Volavka, J | 1 |
| De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 2 |
| Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM | 1 |
| Perlis, RH | 1 |
| Bushe, CJ; Leonard, BE | 1 |
3 review(s) available for aripiprazole and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain | 2007 |
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines; Quinolones; Schizophrenia | 2007 |
10 other study(ies) available for aripiprazole and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus, Type 2; Female; Humans; Islets of Langerhans; Mice; Olanzapine | 2022 |
Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Orexins; Prospective Studies; Schizophrenia | 2022 |
Effects of the second-generation antipsychotic drugs aripiprazole and olanzapine on human adipocyte differentiation.
Topics: Adipocytes; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines | 2023 |
Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia.
Topics: Adult; Aripiprazole; Diabetes Mellitus, Type 2; Humans; Quality of Life; Schizophrenia | 2021 |
Glucose and Prolactin Monitoring in Children and Adolescents Initiating Antipsychotic Therapy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Insurance Claim Review; Japan; Male; Mass Screening; Prolactin; Retrospective Studies; Risperidone | 2018 |
Editorial: Making Use of What We Know: Medical Decision-Making and Antipsychotics.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Child; Clinical Decision-Making; Diabetes Mellitus, Type 2; Humans; Psychotic Disorders; Quetiapine Fumarate | 2019 |
The effects of antipsychotic switching on diabetes in chronic schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Weight Loss | 2014 |
A case series: evaluation of the metabolic safety of aripiprazole.
Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome | 2007 |
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2007 |
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors | 2008 |